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Abstract
Krabbe disease is a severe, fatal neurodegenerative disorder caused by
defects in the lysosomal enzyme galactocerebrosidase (GALC). The cor-
rect targeting of GALC to the lysosome is essential for the degradation
of glycosphingolipids including the primary lipid component of myelin.
Over 100 different mutations have been identiﬁed in GALC that cause
Krabbe disease but the mechanisms by which they cause disease remain
unclear. We have generated monoclonal antibodies against full-length
human GALC and used these to monitor the trafﬁcking and process-
ing of GALC variants in cell-based assays and by immunoﬂuorescence
microscopy. Striking differences in the secretion, processing and endo-
somal targeting of GALC variants allows the classiﬁcation of these into
distinct categories. A subset of GALC variants are not secreted by cells,
not proteolytically processed, and remain trapped in the ER; these are
likely to cause disease due to protein misfolding and should be targeted
for pharmacological chaperone therapies. Other GALC variants can be
correctly secreted by cells and cause disease due to catalytic defects in
the enzyme active site, inappropriate post-translational modiﬁcation or
a potential inability to bind essential cofactors. The classiﬁcation of dis-
ease pathogenesis presented here provides a molecular framework for
appropriate targeting of future Krabbe disease therapies.
Keywords galactocerebrosidase, globoid cell leukodystrophy, glycosph-
ingolipid, Krabbe disease, lysosomal storage disease
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Krabbe disease, also known as globoid cell leukodys-
trophy, is a rare, autosomal recessive disorder in which
extensive demyelination is accompanied by rapid, fatal
neurodegeneration. Krabbe disease is caused by defects
in the lysosomal enzyme galactocerebrosidase (GALC)
that is essential for the catabolism of galactosphingolipids,
including the primary lipid component of myelin, galac-
tocerebroside. The molecular understanding of Krabbe
disease has been aided by the sequence characteriza-
tion of the human gene, structure determination of the
GALC protein and via the study of various animal mod-
els of the disease (1–5). The GALC protein is produced
and glycosylated in the endoplasmic reticulum (ER) and
trans-Golgi network (TGN) where it is post-translationally
modified by N-linked glycosylation at four sites (3).
GALC then becomes cargo for the cation-independent
mannose-6-phosphate receptor (M6PR) which targets it
to lysosomes either directly from the trans-Golgi network
(TGN) or indirectly via secretion and re-uptake (6). It is
in the endolysosome/lysosome that GALC processes lipid
substrates. Sphingolipid degradation by lysosomal hydro-
lases also requires non-enzymatic sphingolipid activator
proteins known as saposins. In rare cases, Krabbe disease
can be caused by lack of functional saposin A (7).
Despite these molecular insights into GALC function the
cellular events that result in apoptosis of myelin-forming
oligodendrocytes and Schwann cells of the central and
peripheral nervous systems remains poorly understood.
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Krabbe disease severity and progression are highly vari-
able and the age of clinical onset can vary from the first
few weeks of life (early infantile) through late-infantile and
juvenile into adult presentations (late-onset). To date, 147
differentmutations in theGALC gene have been catalogued
for the Online Metabolism and Molecular Bases of Inher-
ited Disease (OMMBID) (8).
Currently, the only available treatment forKrabbe disease is
haematopoietic stem cell transplantation but as this cannot
repair damage that has already occurred it must be initi-
ated before the onset of symptoms. For this reason early
diagnosis is crucial and has led to the establishment of sev-
eral newborn screening programmes (9). For mutations of
known severity these screening programmes aid the rapid
implementation of treatment. However, for newly identi-
fied mutations the clinical severity remains uncertain.
Understanding the pathogenesis of specific mutations in
GALC is not only important for predicting the severity of
newly identified mutations but is also important for deter-
mining which patients will be appropriate candidates for
new treatments and combination therapies currently being
developed (10–13). One such therapy being pursued for
Krabbe disease and a number of related lysosomal storage
diseases is pharmacological chaperone therapy (14–18).
The goal of this approach is to treat patients with small
molecules that can bind and stabilize partially misfolded
enzyme that would otherwise remain trapped in the ER
and be degraded by cellular quality-control pathways. This
approach will not be appropriate for patients with large
deletions in theGALC gene or for variants that are catalyti-
cally defective but must instead be targeted towards mis-
sense mutations that cause protein misfolding. For these
reasons, it is important that we understand the molecu-
lar defects caused by specific mutations in GALC. Here
we present the characterization of a series of Krabbe dis-
ease variants and highlight different molecular mecha-
nisms underlying the pathogenesis of this disease.
Results
Missense mutations alter GALC secretion
and processing
In order to understand the different effects of missense
mutations on GALC processing and trafficking a series of
clinically relevant variants were selected and expressed in
HEK293T cells. Two numbering schemes are commonly
used for GALC based on either the first or second methio-
nine in the ER signal sequence. Here we are using the
numbering based on the second methionine as this is con-
sistent with the majority of the literature and the available
structural data. For clarity we have included a table show-
ing the equivalent numbering for the alternative start site
(Table S1, Supporting Information). FLAG-tagged GALC
variants were detected in cell lysates and conditioned
media by western blot. Use of the anti-FLAG antibody in
this case ensures that all GALC variants are detected using
an identical epitope reducing any differences in binding
of the antibody due specifically to the encoded mutation.
All GALC variants are equally expressed in cells and indi-
vidual bands are detected in cell lysates representing the
addition of four N-linked glycans as GALC is produced
and glycosylated in the ER and TGN (Figures 1A and 5B).
However, only a subset of these variants is secreted and
detected in the conditioned media suggesting a defect in
trafficking beyond the ER-TGN (Figure 1A). For those
variants that are secreted, only one band is detectable in the
conditioned media identifying that these proteins possess
uniform glycosylation and are therefore likely to have
undergone correct processing before being secreted from
cells. To confirm this, the sensitivity of GALC glycans to
PNGaseF and EndoH was tested (Figure 1B). The partially
processed protein in the cell lysates was susceptible to
both treatments as expected, while the protein secreted
into the media was primarily EndoH resistant confirming
that the glycans had been correctly modified during their
trafficking through the ER-TGN.
The secretion profile illustrated here for a range ofmissense
mutations provides an initial classification of GALC vari-
ants into those that are correctly processed and secreted
and those that may cause disease due to misfolded protein
being trapped in the ER. To confirm the delivery, or lack
thereof, to the lysosomal compartment there is an addi-
tional post-translational processing step that occurs in the
lysosome. Upon delivery to the lysosome, a loop on the
surface of GALC is cleaved by a lysosomal protease. This
event does not affect activity and is not likely to have any
effect on the structure but can be detected by SDS-PAGE
as 50- and 30-kDa bands (6,19,20). In the previous assays
(Figure 1A,B) there was no detectable band for the lower
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Figure 1: Missense mutations
alter GALC secretion from cells.
HEK293T cells were transiently
transfected with FLAG-tagged
wild-type (WT) GALC and a panel
of clinically relevant Krabbe disease
mutations. Conditioned media was
harvested at 72 h and cells lysed
in 1% SDS followed by SDS-PAGE
and immunoblotting. A) Secreted
and total GALC expression were
detected using western blot with
an anti-FLAG antibody. Actin served
as a loading control. B) Condi-
tioned media and cell lysates were
digested with either EndoH or with
PNGaseF before immunoblotting
with anti-FLAG-to detect GALC.
molecular weight cleavage product expected upon deliv-
ery of GALC to the lysosome. However, as detection of
GALC involved using an antibody against the epitope tag
it was possible that in the proteolytic environment of the
endolysosomal system this tag is cleaved from the GALC
protein restricting detection of the processed form. To
overcome this, we generated a new panel of monoclonal
antibodies raised against the full-length human GALC
protein. We carried out an immunoprecipitation (IP) of
GALC from cell lysates using either the FLAG antibody
or two different mouse monoclonal antibodies (mAb1,
mAb2). Following IP, bands were detected by western
blot using a rabbit polyclonal antibody raised against a
peptide within the smaller C-terminal 30-kDa fragment
(Figure 2A). For all samples the full-length uncleaved
GALC is detectable at approximately 80 kDa. In both the
IPs carried out with monoclonal antibodies an additional
band is present at 30-kDa consistent with the fragment
size following cleavage upon delivery to the lysosome.
This band is not detectable in the IP using the anti-FLAG
antibody highlighting the critical importance of appropri-
ate antibodies for assay development. To confirm that the
cleavage event occurs post-Golgi and thus is a measure
of successful trafficking to lysosomes we carried out an
uptake assay whereby conditioned media containing
full-length uncleaved GALC was applied to untransfected
HEK293T cells (Figure 2B). The appearance of the 30-kDa
fragment in untransfected cells treated with full-length
GALC identifies that the detection of cleaved GALC can
provide a measure of lysosomal delivery of wild-type
(WT) andmutant forms of GALC. Cell lysates fromGALC
missense mutations that are not secreted into the condi-
tioned media, such as R515H and T513M (Figure 1A),
have no detectable 30-kDa cleavage product (Figure 2C)
consistent with these proteins being trapped in the ER due
to misfolding and therefore are not delivered to lysosomes.
Missense mutations that are secreted into the conditioned
media, such as R380W and E215K, show reduced but still
detectable levels of GALC cleavage product.
Non-secreting, unprocessed missense mutations
of GALC are trapped in the ER
Absence of GALC in the conditioned media and the lack
of cleaved product in cell lysates together provide com-
pelling evidence that a particular GALC variant causes
disease due to compromised protein folding and is thus
910 Trafﬁc 2016; 17: 908–922
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Figure 2: Proteolytic cleavage of WT and mutant GALC. A) Protein lysates from either untransfected HEK293T cells or from
cells transfected with WT GALC were subjected to immunoprecipitation with monoclonal antibodies against full-length human GALC
(mAb1 and mAb2) or the FLAG epitope tag. GALC was detected using western blot with a polyclonal rabbit GALC antibody, cleavage
product at ∼30-kDa is marked with an asterisk. B) Conditioned media (CM) from HEK293T cells transfected with WT GALC contains
full-length GALC (lane 1). GALC-containing CM (+) and CM from untransfected cells (−) was harvested after 72 h and applied to
untransfected HEK293T cells for 48 h. Treated cells were subjected to immunoprecipitation using the GALC monoclonal antibody mAb2
and detected as in A. C) HEK293T cells were transiently transfected with WT GALC and Krabbe mutations R380W, E215K, R515H and
T513M and immunoprecipitated using the mAb2 antibody and detected as in A.
retained in the ER. However, both these measures are indi-
rect and so several GALC variants were further tested
by direct monitoring of their cellular localization. GALC
variants were expressed in HeLa cells and detected by
immunofluorescence microscopy using monoclonal anti-
bodies raised against full-length human GALC and com-
pared with markers for the ER (calreticulin, calnexin and
REEP5) and lysosome (cathepsin D). Immunofluorescence
microscopy clearly identifies that WT GALC co-localizes
with cathepsin D identifying its correct trafficking to lyso-
somes (Figure 3A).Missensemutations that were shown to
inhibit secretion of GALC and prevent normal processing
in the lysosome were tested for their cellular localization
(Figure 3B, Figures S1 and S2). T513M and L618S show
clear reticular staining consistent with ER architecture
and very poor co-localization with the lysosomal marker
(Figure 3C). The co-localization of these variants with the
ER markers confirmed their ER localization (Figure 3B,C,
Figure S1). Additional missense mutations I583S, R515H
and Y319C were also identified to co-localize with the ER
markers calreticulin and calnexin (Figure S2).
Missense mutations of GALC that are secreted by cells and
show cleavage consistent with lysosomal localization were
also tested for their cellular localization. The residue R380
has been shown by us previously to be critical for enzyme
activity as it directly binds substrate in the active site (3,21).
In this case, we would expect this mutation not to inter-
fere with folding and to traffic to the lysosome where the
disease-causing defect is primarily catalytic. In agreement
with this, immunostaining of the R380W mutant identi-
fies that it co-localizes with lysosomes to the same extent as
WT GALC (Figure 4A,C). GALC containing the missense
mutation E215K can be secreted into the media and shows
cellular localization similar to WT GALC (Figure 4B).
Consistent with the secretion profile, E215K is not primar-
ily co-localized with the ER marker calreticulin suggesting
that the disease mechanism in this case is not due to a mis-
folding defect (Figure 4C).
N279T introduces a new glycosylation site that
interferes with protein trafﬁcking
The missense mutation N279T is detected in conditioned
media but runs at a slightly higher molecular weight com-
pared with WT and other missense variants (Figure 1A).
Analysis of the sequence surrounding this residue identi-
fies that this mutation introduces a new consensus site for
N-linked glycosylation of residue N277 (Figure 5A). This
additional glycan can be detected in cell lysates and can be
abolished by introduction of the second mutation N277D
Trafﬁc 2016; 17: 908–922 911
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Figure 3: Missense mutations of
GALC that interfere with secretion
and cleavage are trapped in the
ER. Representative confocal microscopy
images of HeLa cells transiently trans-
fected with either WT GALC (A), or the
Krabbe mutations T513M and L618S (B).
Cells were plated onto glass coverslips,
ﬁxed and immunostained using mono-
clonal antibody against GALC (green),
the lysosomal marker cathepsin D (red)
or the ER marker calreticulin (red). Nuclei
were stained with DNA-binding dye,
DAPI (blue). Scale bar: 10 μm. C) To
quantify colocalization, Pearson’s corre-
lation coefﬁcients were calculated for
each variant with both cathepsin D and
calreticulin. Mean± SEM for at least 20
individual cells from ≥3 independent
experiments are shown. ***p≤ 0.0001,
calculated using a two-tailed unpaired
t-test.
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Figure 4: Missense muta-
tions R380W and E215K are
trafﬁcked to the lysosome.
Representative confocal microscopy
images of HeLa cells transiently
transfected with Krabbe mutations
R380W (A) and E215K (B). Trans-
fected cells were plated onto glass
coverslips, ﬁxed and immunostained
for GALC (green), the lysosomal
marker cathepsin D (red) or the ER
marker calreticulin (red). Scale bar:
10 μm. C) Pearson’s correlation
coefﬁcients were calculated for each
of the mutations with both cathep-
sin D and calreticulin. Mean± SEM
for at least 20 individual cells from
≥3 independent experiments are
shown. **p≤ 0.005, *p≤ 0.05,
ns= not signiﬁcant, calculated
using a two-tailed unpaired t-test.
to block glycosylation of this residue (Figure 5B). Unlike
other secreted GALC variants, N279T does not localize to
lysosomes (Figure 5C). Introduction of an additional gly-
can at residue N277 would be predicted to destabilize the
fold of this GALC variant as this residue is deeply buried at
the interface between two domains (Figure 5D). Although
introduction of the second mutation N277D blocks addi-
tion of the extra glycan, the double mutant does not res-
cue trafficking to the lysosome (Figure 5C). Despite the
conservative nature of the introduced N277D mutation,
this change alone causes misfolding of GALC such that it
is not trafficked to the lysosome (Figure 5C). The obser-
vation that N279T can be secreted but not enter the
endocytic pathway suggests that some protein can escape
ER-associated quality control but is defective for binding
to the M6PR. To test this, an uptake assay was carried out
whereby conditioned media containing the N279T variant
was applied to untransfected cells in a manner similar to
Trafﬁc 2016; 17: 908–922 913
Spratley et al.
Figure 5: N279T is a hyperglycosylation
mutant with defective trafﬁcking. A) Protein
sequence of WT and N279T GALC illustrating the
introduction of a new consensus glycosylation site
(NXT). B) HEK293T cells transiently transfected
with WT GALC, Krabbe mutation N279T or double
mutant N279T/N277D were lysed with 1% SDS,
separated by SDS-PAGE and immunoblotted. Total
GALC expression was analysed using western
blot against the FLAG epitope tag. C) HeLa cells
were transiently transfected with Krabbe mutation
N279T, the double mutation N279T/N277D or
N277D alone, plated and ﬁxed on glass coverslips
and immunostained for GALC (green) and the
lysosomal marker cathepsin D (red). Scale bar:
10 μm. D) The newly glycosylated residue, N277,
is highlighted on the structure of GALC (PDB
ID: 3ZR5). The structure is coloured according to
domain (TIM barrel in blue, β-sandwich in red
and lectin domain in green). Zoomed view (inset)
shows the N277 sidechain as sticks. E) Conditioned
media from either untransfected HEK293T cells (−)
or cells transfected with WT or Krabbe mutation
N279T (+) was harvested after 72 h and applied
to untransfected HEK293T cells for 48 h. Treated
cells were subjected to immunoprecipitation using
the GALC monoclonal antibody mAb2. GALC was
detected using western blot with a polyclonal rabbit
GALC antibody.
that shown for WT GALC (Figure 5E). Unlike WT GALC,
the N279T variant cannot be taken up by cells suggesting
that the additional glycan interferes with endocytosis.
The polymorphism at position 546 has subtle effects
on enzyme activity, stability and trafﬁcking
The missense mutations described here have been tested
in the most common polymorphic background I546.
However the polymorphism T546 has been reported
to be present within the population at allele frequency
of 40–45% (22). Clinical assays for GALC activity in
peripheral blood have suggested that the T546 variant has
half the activity of the I546 variant, contributing to the
highly variable ‘normal’ activity levels within the general
population (22–24). In order to test the effect of this
polymorphism on GALC activity we generated stable
expression constructs of each of these polymorphisms
and selected high-yield clones in order to purify mil-
ligram quantities of GALC for steady-state kinetic studies
(Figure 6A and Table S2). Surprisingly, the two variants
do not have significantly different catalytic properties in
vitro: T546 has 89% activity of I546 suggesting that the
914 Trafﬁc 2016; 17: 908–922
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observed differences in activity from blood samples may
be due to differential stability, expression or trafficking in
cells. Thermal denaturation of secreted GALC monitored
by differential scanning fluorimetry DSF revealed a subtle
destabilization of the T546 variant in vitro (Figure 6B;
Tm, I546= 51.8± 0.2∘C versus Tm, T546= 50.6± 0.2∘C).
To determine whether this degree of destabilization was
sufficient to impair trafficking of GALC the presence of
T546 in conditioned media was monitored. Interestingly,
this variant was not detectable in the media suggesting it
is trapped in the ER (Figure 7A). However, if this poly-
morphism completely blocked trafficking of GALC to the
lysosome this would represent a disease-causing mutation.
Cellular localization of T546 by immunofluorescence
microscopy confirms that although this variant is not
detected in conditioned media it can be trafficked to the
lysosome (Figure 7B). The combination of multiple, subtle
deleterious effects on activity, stabilization and trafficking
of the T546 variant may explain the observed reduction in
enzyme activity from peripheral blood samples.
Although the I546T polymorphism on its own has only
subtle effects on GALC function, when combined with
additional missense mutations the cumulative effects can
become severe. Indeed, it has been suggested previously
that certain mutations are only disease-causing in spe-
cific polymorphic backgrounds (25). The G270D variant
is responsible for a late-onset form of Krabbe disease and
is usually found in cis with the I546T polymorphism (26).
In the I546 background, the G270D variant possesses WT
levels of protein secreted into the media and WT local-
ization to lysosomes (Figure 7A,C). However, in the T546
background, theG270Dmutation is severely compromised
in its cellular trafficking and is not localized to lysosomes
(Figure 7A,C, Figure S3). The cumulative effect of these
two sequence variations is not due to a single localized
structural perturbation as the two residues, G270 and I546,
lie in distant parts of the GALC structure (Figure 7D).
Specifically, G270 is situated near the disulphide bond that
stabilizes a critical active-site loop structure while residue
546 lies in the C-terminal lectin domain.
The missense mutation Y551S causes infantile Krabbe
disease and has been identified in the T546 polymorphic
background (26). These two residues are much closer to
each other in theGALC structure and somight be expected
Figure 6: Effect of the I546T polymorphism on enzyme
activity and stability. A) Michaelis–Menten plots of initial
velocity versus substrate concentration at GALC concentrations of
0.420 nM ( ), 0.842 nM, ( ), 1.68 nM, ( ), 3.37 nM, ( ), 6.73 nM,
( ), and 13.4 nM ( ). (Inset) Plot of Vmax observed versus GALC
concentration showing kcat as the gradient (11.9/sec for I546 and
10.6/sec for T546). Experiments were performed in triplicate and
SEM error bars are shown. B) Differential scanning ﬂuorimetry of
GALC polymorphisms I546 ( ) and T546 ( ) demonstrate similar
thermal denaturation proﬁles.
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Figure 7: Polymorphic background alters the trafﬁcking of some missense mutations. A) HEK293T cells were transiently
transfected with WT GALC (I546), T546, Y551S-I546, Y551S-T546, G270D-I546, G270D-T546. Conditioned media was harvested at
72 h and cells lysed in 1% SDS followed by SDS-PAGE and immunoblotting. Secreted and total GALC expression was detected using
western blot against the FLAG epitope tag and loading analysed by blotting against actin. B) Representative confocal microscopy
images of HeLa cells transiently transfected with WT GALC containing the T546 polymorphism. Cells were plated onto glass coverslips,
ﬁxed and immunostained for GALC (green), the lysosomal marker cathepsin D (red). Nuclei were stained with DNA-binding dye, DAPI
(blue). Scale bar 10 μm. To quantify colocalization Pearson’s correlation coefﬁcients were calculated for cathepsin D. Mean± SEM for
at least 20 individual cells from ≥3 independent experiments are shown. C) Equivalent confocal microscopy images as in panel B
for Y551S-I546, Y551S-T546, G270D-I546 and G270D-T546. D) The positions of I546T, G270D and Y551S are highlighted on the
structure of GALC (PDB ID: 3ZR5). The structure is coloured as in Figure 5. For each variant, the zoomed view (inset) shows the relevant
side chain as sticks and the surrounding region of the structure that would be affected by the mutation. The single disulphide bond
(yellow) present in GALC is illustrated as spheres.
to have a severe cumulative effect on folding (Figure 7D).
However, the secretion profile of this mutation shows that
even in the I546 background the Y551S mutation has a
severe detrimental effect on protein folding and secretion
(Figure 7A). In agreement with this, the Y551S variant in
both polymorphic backgrounds does not traffic correctly
to lysosomes (Figure 7C and Figure S3).
Discussion
In order to better understand the underlying molecular
mechanisms causing GALC dysfunction in Krabbe dis-
ease, clinically relevant variants of GALC were expressed
in cells and monitored for their capacity to traffic beyond
the ER-TGN and to localize to their site of action in
916 Trafﬁc 2016; 17: 908–922
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lysosomes. Using a series of cell-based assays we have
identified the underlying pathogenesis for a number of
these variants. Initial screening of the secretion profile of
GALC variants provides a good first indication of whether
a mutation may result in protein misfolding. The protein
quality control pathways present in the ER should result in
the retention and degradation of misfolded protein. In this
case misfolded GALC will not traffic beyond the ER and
thus will not be detected in the conditioned media. Using
this approach we identified seven variants (Y319C, L618S,
G41S, T513M, I583S, R515H and R63H) that are likely to
cause disease due to protein misfolding. Another subset
of GALC variants (R380W, E215K, N279T, P302R and
R380L) were present in the conditioned media identifying
that the underlying pathology in these cases is not primar-
ily protein misfolding. A further assay was used to monitor
trafficking beyond the ER-TGN by exploiting the observa-
tion that upon delivery of GALC to lysosomes, a 30-kDa
cleavage product can be identified following SDS-PAGE
and immunoblotting. In support of their predicted defect
in protein folding, two of themissensemutations identified
as non-secretors, R515H and T513M, were not processed
into this smaller fragment. Consistent with the secretion
assay, two of the secreted variants (R380W and E215K)
were shown to undergo proteolytic processing similar to
that seen for WT GALC.
Lack of protein secretion and the inability to be processed
into the 50- and 30-kDa fragments are indicative of a
misfolded GALC variant suggesting it is retained in the
ER. To further test this, the cellular localization of GALC
variants was directly monitored by immunofluorescence
microscopy using newly generated, specific monoclonal
antibodies raised against full-length humanGALCprotein.
Using this approach, the GALC variants, T513M, L618S,
Y319C, I583S and R515H were not localized to lysosomes
and were trapped in the ER (Figure 3, Figure S1 and S2).
These GALC variants can be classified as protein misfold-
ing mutants due to their lack of secretion, inability to be
proteolytically processed and their retention in the ER.
Those disease variants that do not result in significant mis-
folding, based on their secretion, processing and cellular
localization, fall into a number of categories. The residue
R380 has been shown by us previously to play a critical role
in the catalytic processing of substrates (3,21). In support of
this, R380WandR380L are secreted similarly toWTGALC
andR380Wwas shown to localize to lysosomes. E215Kwas
also normally secreted and trafficked within the cell but is
not likely to be catalytically defective as this mutation does
not lie near the enzyme active site. This residue is on the
surface of GALC and the charge inversion caused by this
mutation may interfere with important interactions with
partner proteins such as saposin A. The mutation N279T
was shown to introduce a new glycosylation consensus
sequence resulting in the addition of an N-linked glycan
to residue N277. This variant is capable of being secreted
by cells and so can pass ER quality control but is unable to
be taken up by cells or traffic to lysosomes suggesting that
the new glycan may interfere with endocytosis by altering
binding to the M6PR.
A number of polymorphisms have been identified in the
GALC gene and have been shown to have a negative effect
on GALC activity. In this study we produced both the I546
and T546 variants of GALC and compared their activity
and stability in vitro. Surprisingly this polymorphism has
only a subtle effect on GALC enzyme kinetics and ther-
mal stability but did have a significant effect on its traf-
ficking beyond the ER-TGN. This suggests that the lower
activity reported for this polymorphism is a reflection of its
reduced trafficking rather than its inability to process sub-
strate. It has been shown previously that the polymorphic
background that a missense mutation occurs can critically
change the disease pathogenesis (25,27). In agreement with
this, we show that G270D only results in protein misfold-
ing, as measured by ER co-localization, when present in
the T546 background. Thus in this case, it is the combina-
tion of two subtle defects that results in disease. However,
despite the Y551S variant only being identified in the T546
background, it results in protein misfolding in both poly-
morphic backgrounds identifying that this mutation alone
is sufficient to cause significant protein misfolding.
The availability of structural data for GALC allows pre-
diction of the functional effects of missense mutations:
the greater proportion of a side chain that is buried in
the structure the greater the likelihood that a mutation
of that residue will disrupt the fold (3). These predictions
can now be compared with the functional effects identi-
fied here (Table S3).The side chains for residues G41, Y319,
T513, I583 and L618 are completely buried in the structure
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suggesting that mutation of these would result in misfold-
ing and in agreement with this prediction, all were not
secreted by cells and/or were localized to the ER. However,
G270 is also completely buried but the G270D variant is
only localized to the ER when present in the T546 back-
ground. The side chains of R63, R515 and Y551 are also
primarily (∼80%) buried in the structure and are here iden-
tified as non-secretors identifying that even only partially
buried residues can significantly disrupt folding. However,
based on buried surface area, P302 would also fall into this
category but is shown here to be secreted in disagreement
with the structure-based prediction. E215 andR380 are rel-
atively exposed on the surface of GALC (only 57% and 48%
buried) suggesting that residues that are <60% buried are
unlikely to result in misfolding. On the basis of this analy-
sis, the structure provides a good molecular framework for
making predictions but verification in cell-based assays is
still required.
In this study we have used three different assays to mon-
itor trafficking defects in GALC variants. Each assay has
different levels of complexity and sensitivity allowing a
confidence level to be associated with the designation of
the molecular defect caused by a specific mutation. The
importance of using multiple assays is best highlighted
by those variants that have subtle effects such as the
I546T polymorphism. Although this polymorphism is not
disease-causing, in our secretion assay it is not detectable
suggesting that this assay alone is not sufficiently sensi-
tive to distinguish subtle GALC defects. However, moni-
toring cellular localization by immunostaining appears to
be much more sensitive as in this case the polymorphic
variant can be localized to lysosomes. Thus although the
secretion assay is a fast and convenient readout it is impor-
tant that conclusions regarding the underlying pathogene-
sis of subtle variants be confirmed using the more sensitive
co-localization assay.
Extrapolation from disease mechanism to disease sever-
ity remains highly challenging.The disease-causing variant
L618S has a complex effect in patients and has been identi-
fied in patients with age of onset ranging from late-infantile
to adult (28–30). This variation in disease severity is likely
influenced by many factors including the polymorphic
background and compound heterozygosity both of which
have been documented for this variant. Recently, Shin et al.
also showed that L618S is severely compromised in its abil-
ity to be correctly processed into the 50- and 30-kDa frag-
ments supporting a defect in folding (31). However, unlike
our localization studies identifying L618S as trapped in
the ER, Shin et al. found some evidence that this variant
co-stains with LAMP2 suggesting it maintains some capac-
ity to be delivered to late endosomes/lysosomes. For this
reason one must be cautious to assign degree of disease
severity based on these assays but should instead use the
identification of the nature of the defect as a critical factor
for subsequent therapeutic targeting. Mutations that cause
misfolding, giving rise to lack of secretion, processing and
primarily ER co-localization, may be good targets for phar-
macological chaperone therapies while those that retain
significant capacity for correct trafficking and processing
will require future enzyme replacement approaches. How-
ever, the extent of misfolding caused by specific mutations
will alter the effectiveness of pharmacological chaperones.
Specifically, the misfolding caused by some mutations may
prove too severe to respond to these approaches and will
therefore require enzyme replacement strategies.
Studies in related lysosomal storage disorders have exam-
ined the effects of missense mutations on enzyme process-
ing and trafficking. Retention of misfolded protein in the
ER is an important factor in specific variants that cause
Gaucher disease (32–35), Pompe disease (36) and GM1
gangliosidosis (37). In several cases, this insight has been
used to examine if pharmacological chaperones, ERAD
inhibitors and proteostasis regulators can rescue thesemis-
folded variants and restore trafficking to the lysosome.
Although these studies have provided some potential leads
for therapeutic development, they have also highlighted
that these approaches are often only successful with a lim-
ited subset of mutations potentially due to the severity of
the misfolding defect (mentioned above). One of the cur-
rent limitations in drug development for Krabbe disease is
the lack of reliable high-throughput (HT) approaches for
the screening of new therapeutics against the wide range
of mutations present in the patient population. Although
activity measurements can be carried out in a HT man-
ner (38), previous work has shown that GALC activity does
not correlate well with disease severity and may not pro-
vide a good measure for treatment efficacy (25,31). One of
the primary reasons for this may be attributed to the fact
that the activity assays are often conducted on whole cell
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lysates and so cannot distinguish between protein that is
localized in the ER or the endocytic pathway leaving the
question as to whether the active protein is still mislocal-
ized unanswered. Recent work measuring the activity of
samples enriched for the lysosomal fraction show a better
correlation with disease severity providing a good first step
towards more reliable activity measurements (31). Future
development of the assays described here into a HT format
would provide a complementary readout to these activity
assays and confirm those conditions where GALC is suc-
cessfully trafficked beyond the ER-TGN and thus corrected
for misfolding defects.
Materials and Methods
Cloning and mutagenesis of human GALC constructs
For large-scale protein expression in mammalian cells wild-type human
GALC (hGALC) polymorphisms I546 and T546 were cloned into pSec-
Tag2B vector with an N-terminal His6 tag and stable HEK293T cell
lines were established and cultured as described previously (3). For tran-
sient expression of mutants in mammalian tissue culture mutant hGALC
constructs were generated in the pSecTag2b vector by Quikchange site
directedmutagenesis ofwild-type hGALC in either the I546 or T546 back-
ground (as indicated). Constructs were then sub-cloned into the pHLsec
vector resulting in removal of the His tag and addition of a C-terminal
FLAG epitope tag.
Expression and puriﬁcation of human GALC protein
Large-scale expression and IMAC-affinity purification of hGALCproteins
from HEK293T cells for antibody (Ab) generation, activity assays and
thermal denaturation experimentswas carried out as described previously
for the equivalent mouse GALC constructs (21,39).
Monoclonal antibody generation
Monoclonal mouse anti-human GALC antibodies were raised against
full-length secreted human GALC protein. Mice were immunized sub-
cutaneously 2 times with 25 μg of purified human GALC, mixed with
GERBU® adjuvant. Before 3 days of fusion, the mice received an intra-
venous (i.v.) injection with 10 μg of antigen together with adrenalin.
Spleen cells and SP2 myeloma cells were used for fusion. Positive clones
were selected and cloned by repeated screening against the GALC protein
using enzyme-linked immunosorbent assay (ELISA). The performance
and specificity of several antibody cloneswere validated usingwestern blot
and immunofluorescence microscopy against transfected cells.
Cell culture
HEK293T and HeLa cells were maintained in Dulbecco’s Modified
Eagle Medium supplemented with 10% foetal bovine serum, 50U/mL
penicillin, 50 μg/mL streptomycin and 4mM L-glutamine. Cells were
maintained at 37∘C in humidified air with 5% CO2. HEK293T cells used
for immunoblot studies were grown in Freestyle 293 expression medium
and transiently transfected using Lipofectamine-2000 transfection
reagent. HeLa cells used for immunostaining were transiently transfected
at 40% confluence using the TransIT-HeLa Monster transfection reagent.
For GALC uptake assays, serum-free conditioned media from transfected
or untransfected cells was harvested and filtered 72 h post-transfection
and then applied to untransfected cells for 48 h. Cells were lysed in 1%
Triton X-100 and subjected to immunoprecipitation using monoclonal
mouse anti-GALC antibody in the presence of protein A sepharose beads.
GALC cellular uptake was detected by immunoblot, as described below.
Immunoblotting and immunoprecipitation of GALC
Secreted protein was detected from conditioned media harvested 72 h
post-transfection. Cells were lysed in either 1%Triton X-100 or 1% SDS in
Tris-buffered saline (TBS, 20mM Tris–HCl, 150mM NaCl, 5mM MgCl2,
1mM EDTA) in the presence of 10mM N-ethylmaleimide (NEM), 1mM
phenylmethylsulfonyl fluoride (PMSF) and protease inhibitors. Where
appropriate, protein concentration was quantified via bicinchoninic acid
(BCA) assay. For immunoprecipitation, 1000 μg cell lysate was pre-
cleared using IgG/protein A-sepharose beads. Pre-cleared lysate was
incubated with anti-FLAG or anti-GALC antibodies in the presence of
A-sepharose beads and washed in TBS supplemented with 0.1% Triton
X-100. All samples were denatured and reduced in SDS loading buffer
containing 20mM DTT prior to SDS-PAGE separation. For immunoblot
studies, proteins were transferred to methanol-activated Immobilon-FL
polyvinylidene fluoride (PVDF) membrane. After blocking, membranes
were incubated with primary antibody followed by incubation with
infrared fluorophore-conjugated secondary antibody. Immuno-reactive
bands were visualised with an Odyssey infrared imager (LI-COR Bio-
sciences).
Confocal immunoﬂuorescence microscopy
Cells were grown on glass coverslips, washed with PBS and fixed in 4%
PFA. Fixed cells were washed in PBS, quenched with 15mM glycine and
permeabilised in 0.1% saponin in PBS. Fixed cells were blocked in 1%
BSA, 0.01% saponin in PBS before incubation with primary antibody
diluted in 1%BSAwith 0.01% saponin followed by fluorescent-conjugated
secondary antibody. Coverslips were mounted onto slides using mount-
ing medium with DAPI (Prolong Antifade, Invitrogen Molecular Probes).
Images were acquired on a Zeiss LSM880 confocal microscope with ZEISS
ZEN software. To analyse co-localization, intensities were measured for
≥20 individual cells from ≥3 independent experiments and Pearson’s
correlation coefficients were calculated using the VOLOCITY 5.2 software
(Perkin Elmer). Automatic Costes thresholds were applied to all images
(40). Significance was calculated using two-tailed t-tests implemented
in PRISM5 (GRAPHPAD), error bars represent SEM. Endogenous GALC is
not detectable by immunostaining of untransfected HeLa cells (Figure
S4A,B). HeLa cells transfected with the N-terminally His-tagged con-
struct of GALC show equivalent cellular localization as the C-terminally
FLAG-tagged construct (Figure S4, C).
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Antibodies
The antibodies used for immunostaining were: monoclonal mouse
anti-GALC clone mAb6 (described above), polyclonal rabbit
anti-cathepsin D (Calbiochem), polyclonal rabbit anti-calreticulin
(Pierce), polyclonal rabbit anti-calnexin (Abcam), polyclonal rabbit
anti-REEP5 (proteintech), polyclonal goat AlexaFluor488-conjugated
anti-mouse IgG (Life Technologies) and polyclonal goat
AlexaFluor555-conjugated anti-rabbit IgG (Life Technologies). Anti-
bodies used for immunoblotting were: monoclonal mouse anti-FLAG
(Sigma), monoclonal mouse anti-GALC clones mAb1 and mAb2
(described above), polyclonal rabbit anti-GALC (Abcam), polyclonal rab-
bit anti-actin (Sigma), polyclonal goat IRdye680-conjugated anti-rabbit
IgG (LiCor) and polyclonal goat IRdye800-conjugated anti-mouse
IgG (LiCor).
Deglycosylation of GALC
Conditioned media and cells lysed in 1% SDS (as described above) were
denatured at 100∘C for 10min and were either subjected to EndoH or
PNGaseF treatment (NEB) for 4 h at 37∘C.
Enzyme activity assays
Activity assays were carried out as described previously (21). In brief,
activity assays were carried out at 37∘C using purified hGALC in
20mM sodium acetate, 150mM NaCl, 0.1% v/v NP-40, pH 4.6 and
chromogenic substrate 4-nitrophenyl-β-D-galactopyranoside (4NβDG).
Product 4-nitrophenol was monitored by absorbance at 410 nm fol-
lowing addition of stopping buffer (360mM NaOH, 280mM glycine,
pH 10.6). Km and Vmax were obtained from plots of initial veloc-
ity against substrate concentration by non-linear curve-fitting to
the Michaelis–Menten equation using PRISM5 (GRAPHPAD). kcat was
determined as the gradient of the linear plot of Vmax against enzyme
concentration.
Differential scanning ﬂuorimetry (DSF)
DSF experiments were carried out as described previously (39). In brief,
5 μg of purified hGALC in PBS, pH 7.4 was combined with 5× SyPRO
Orange dye prior to thermal denaturation performed using a Bio-Rad
MiniOpticon RT-PCR thermal cycler. The melting temperature (Tm) was
the inflexion point of the sigmoidal curve obtained by curve fitting using
DSF analysis scripts and PRISM5 (GRAPHPAD).
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Supporting Information
Additional Supporting Information may be found in the online version of
this article:
Table S1: Missense mutations of GALC described in the text. This
table is first associated with Figure 1 but is relevant to the whole paper
and describes the alternative numbering used in the literature allowing
for greater clarity when comparing with other published data using this
numbering scheme.
Table S2: Enzyme activity of WT GALC I546 and the T546 polymor-
phism. This table is associated with Figure 6 and provides the details of
the enzyme activity values Km, Vmax and kcat calculated from the data in
Figure 6.
Table S3: Proportion of side chain buried in the structure, prediction
and identified defect. This table is associated with the Discussion and
summarises the correlation between the buried surface area of a side chain
as calculated from the structure and the predicted effect this would have
on the protein compared with the molecular mechanism identified in
this work.
Figure S1: Colocalization of T513M and L618S missense mutations
with additional ER markers. This figure provides additional representa-
tive confocal images of T513MandL618S colocalizedwith the ERmarkers
calnexin and REEP5. These images are associated with Figure 3.
Figure S2: Colocalization of additional missense mutations of GALC
with ER markers. This figure provides representative confocal images of
additional missense mutations I583S, R515H and Y319C showing colo-
calization with the ER markers calreticulin and calnexin. These images
are associated with Figure 3.
Figure S3: Effect of polymorphic background on trafficking of G270D
andY551S.This figure provides additional representative confocal images
of G270D and Y551S in both polymorphic backgrounds colocalized with
the ER marker REEP5. These images are associated with Figure 7.
Figure S4: Representative confocal images from untransfected HeLa
cells and cells expressing N-terminally tagged GALC constructs. This
figure provides evidence that endogenous GALC is not detectable in
untransfected HeLa cells and that a construct of GALC possessing a tag at
the N-terminus displays similar cellular localization as the C-terminally
tagged construct.This figure is associated with theMaterials andMethods
section.
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